Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of BOS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)

NCT03780517 is registered in ClinicalTrials.gov with Boston Pharmaceuticals as lead sponsor.

NCT NCT03780517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03780517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of BOS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)
Lead sponsor
Boston Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
December 12, 2018
Completion date
September 26, 2023
Enrollment
117 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

advanced nonhaematologic malignancies